Search Results Search Sort by RelevanceMost Recent Policy Forum Feb 2022 Por qué los enfoques no carcelarios basados en la atención para las personas detenidas con enfermedades mentales son clave para volver a confiar o no en los profesionales o la autoridad estatal Frederic G. Reamer, PhD AMA J Ethics. 2022;E145-149. doi: 10.1001/amajethics.2022.145. Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Policy Forum Mar 2023 What Should Be Clinicians’ Roles in Regulatory Assessment of Prospective Interventions’ Risks of Exacerbating Inequity? Anushka Bhaskar and Daniel Carpenter, PhD When regulatory decisions express overconfidence, one risk is that the costliness or misinformation will exacerbate health inequity. AMA J Ethics. 2023;25(3):E204-209. doi: 10.1001/amajethics.2023.204. Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056. Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063. Policy Forum Nov 2022 Necessity for and Limitations of Price Transparency in American Health Care Harold A. Pollack, PhD, MPP More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline. AMA J Ethics. 2022;24(11):E1069-1074. doi: 10.1001/amajethics.2022.1069. Policy Forum Sep 2022 Roles of Environmental Services Workers’ Wages and Status in Patient Safety David Sine, DBioethics and Lloyd Duplechan This article offers a risk management standpoint on environmental services as a mission-critical function of any health care organization. AMA J Ethics. 2022;24(9):E876-882. doi: 10.1001/amajethics.2022.876. In the Literature Aug 2003 The Pediatrician's Role in Family Decision Making Susanna Smith Virtual Mentor. 2003;5(8):322-324. doi: 10.1001/virtualmentor.2003.5.8.jdsc2-0308. Policy Forum Oct 2003 Psychotropic Medications and Criminal Defendants Robert M. Wettstein, MD Virtual Mentor. 2003;5(10):455-459. doi: 10.1001/virtualmentor.2003.5.10.pfor1-0310 Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Next page Next › Last page Last »
Policy Forum Feb 2022 Por qué los enfoques no carcelarios basados en la atención para las personas detenidas con enfermedades mentales son clave para volver a confiar o no en los profesionales o la autoridad estatal Frederic G. Reamer, PhD AMA J Ethics. 2022;E145-149. doi: 10.1001/amajethics.2022.145.
Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Policy Forum Mar 2023 What Should Be Clinicians’ Roles in Regulatory Assessment of Prospective Interventions’ Risks of Exacerbating Inequity? Anushka Bhaskar and Daniel Carpenter, PhD When regulatory decisions express overconfidence, one risk is that the costliness or misinformation will exacerbate health inequity. AMA J Ethics. 2023;25(3):E204-209. doi: 10.1001/amajethics.2023.204.
Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056.
Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063.
Policy Forum Nov 2022 Necessity for and Limitations of Price Transparency in American Health Care Harold A. Pollack, PhD, MPP More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline. AMA J Ethics. 2022;24(11):E1069-1074. doi: 10.1001/amajethics.2022.1069.
Policy Forum Sep 2022 Roles of Environmental Services Workers’ Wages and Status in Patient Safety David Sine, DBioethics and Lloyd Duplechan This article offers a risk management standpoint on environmental services as a mission-critical function of any health care organization. AMA J Ethics. 2022;24(9):E876-882. doi: 10.1001/amajethics.2022.876.
In the Literature Aug 2003 The Pediatrician's Role in Family Decision Making Susanna Smith Virtual Mentor. 2003;5(8):322-324. doi: 10.1001/virtualmentor.2003.5.8.jdsc2-0308.
Policy Forum Oct 2003 Psychotropic Medications and Criminal Defendants Robert M. Wettstein, MD Virtual Mentor. 2003;5(10):455-459. doi: 10.1001/virtualmentor.2003.5.10.pfor1-0310